View Document Preview and Link
Document Date: 2015-06-29 12:01:45 Open Document File Size: 145,79 KB Share Result on Facebook
Company TxCell SA / Trizell Holding SA / / Continent Europe / / Country Germany / Italy / Belgium / France / Austria / United States / United Kingdom / / / Event FDA Phase / / Facility EU GMP facility / France’s National Institute / / / IndustryTerm biotechnology / treatment of autoimmune uveitis / a rare disease / technology park / cellular immunotherapy technology / treatment of severe chronic inflammatory diseases / cells products / manufacturing site / cell immunotherapy product / spin-off / / MedicalCondition autoimmune uveitis / refractory Crohn’s disease / severe refractory Crohn’s disease / autoimmune diseases / disease / rare disease / severe chronic inflammatory diseases / inflammatory / / MedicalTreatment immunotherapies / immunotherapy / cell therapy / / Organization Communication Department / United States Food and Drug Administration / Dr Frederik Paulsen Foundation / France’s National Institute for Health and Medical Research / FDA / European Union / Ferring International Center / / Person Stéphane Boissel / Pierre Laurent / Neil Hunter / Emma Marshall Julien Perez / Miguel Forte / / / Position Chief Executive Officer / Chief Operating Officer / hunter / marshall / / Product ASTrIA / a unique and proprietary product platform / Ovasave / Investigational New Drug / ASTrIA / Ovasave® / CATS29 / / ProvinceOrState Indiana / / Technology cell therapy / biotechnology / cellular immunotherapy technology / / SocialTag